Alkermes plc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
Alkermes plc. (ALKS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of $25.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2022-11-02
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2022-09-30 was -$4.00K, a 157.14% decline year-over-year.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2022-06-30 was -$11.00K, a 1200.00% decline year-over-year.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2022-03-31 was $40.00K, a 122.22% increase year-over-year.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for the quarter ending 2021-12-31 was $13.00K, a 1200.00% increase year-over-year.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2021 was $39.00K, a 457.14% increase from fiscal 2020.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2020 was $7.00K, a 99.93% decline from fiscal 2019.
- Alkermes plc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2019 was $10.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$15.00K derived: sum of 2 quarters · filed 2022-11-02 | $25.00K 10-Q · filed 2022-11-02 | $38.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $29.00K 10-Q · filed 2022-07-27 | $42.00K derived: sum of 3 quarters · filed 2022-07-27 | $49.00K derived: sum of 4 quarters · filed 2022-07-27 |
| 2022-03-31 | $40.00K 10-Q · filed 2022-04-27 | $53.00K derived: sum of 2 quarters · filed 2022-04-27 | $60.00K derived: sum of 3 quarters · filed 2022-04-27 | $61.00K derived: sum of 4 quarters · filed 2022-04-27 |
| 2021-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $20.00K derived: sum of 2 quarters · filed 2022-02-16 | $21.00K derived: sum of 3 quarters · filed 2022-02-16 | $39.00K 10-K · filed 2022-02-16 |
| 2021-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $8.00K derived: sum of 2 quarters · filed 2021-10-27 | $26.00K 10-Q · filed 2021-10-27 | $27.00K derived: sum of 4 quarters · filed 2021-10-27 |
| 2021-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $19.00K 10-Q · filed 2021-07-28 | $20.00K derived: sum of 3 quarters · filed 2021-07-28 | -$11.00K derived: sum of 4 quarters · filed 2021-07-28 |
| 2021-03-31 | $18.00K 10-Q · filed 2021-04-28 | $19.00K derived: sum of 2 quarters · filed 2021-04-28 | -$12.00K derived: sum of 3 quarters · filed 2021-04-28 | |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$30.00K derived: sum of 2 quarters · filed 2021-02-11 | $7.00K 10-K · filed 2021-02-11 | |
| 2020-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $6.00K 10-Q · filed 2020-10-29 | ||
| 2020-06-30 | $37.00K 10-Q · filed 2020-07-29 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $10.00M 10-K · filed 2020-02-13 | ||
| 2019-09-30 | $10.00M 10-Q · filed 2019-10-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |